Stay updated with breaking news from Jay Pepose. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended 2021 and Provides Corporate Update Building Momentum with Completion of Patient... | March 24, 2022
New data support Phase 3 development of Nyxol alone as a durable single eye drop for the potential treatment of Presbyopia First update on recruitment in APX3330 ZETA-1 Phase 2b trial: ~70% patients... | January 31, 2022
FARMINGTON HILLS, Mich, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...
Highlights of Recent Positive Data from Nyxol's Phase 3 Registration Trial Roundtable Discussion by 3 KOLs with Unique Perspectives and Distinct Patient ...
Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances January 05, 2021 07:00 ET | Source: Ocuphire Pharma Ocuphire Pharma Nyxol is in Late Stage Clinical Development for A New Ophthalmic Indication Top Line Data from LYNX-1 Expected 3Q2021 FARMINGTON HILLS, Mich., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced the initiation of patient recruit...